Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$41.71 USD

41.71
3,332,742

+0.28 (0.68%)

Updated Aug 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto

by Zacks Equity Research

Novartis (NVS) announced strong results for the fourth quarter as earnings and sales both beat estimates driven by Cosentyx and Entresto sales which more than offset the decline in Gleevec sales.

    What's in the Cards for Biogen (BIIB) This Earnings Season?

    by Zacks Equity Research

    On the Q4 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise, and Spinraza's performance.

      Amgen/Allergan's Avastin Biosimilar Secures EU Approval

      by Zacks Equity Research

      Amgen (AMGN) and Allergan's Mvasi - a biosimilar version of Roche's cancer drug, Avastin - gets marketing approval in the EU.

        Cancer Space Update: Label Expansions, Data Readouts in Focus

        by Zacks Equity Research

        This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.

          BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa

          by Zacks Equity Research

          BioLineRx (BLRX) posts encouraging partial results from the monotherapy portion of a phase IIa COMBAT study, assessing its lead pipeline candidate, BL-8040, for pancreatic cancer patients.

            Merck Strong on Confirmatory Phase III Lung Cancer Study

            by Zacks Equity Research

            Merck's (MRK) Keytruda in combination with Eli Lilly's Alimta and carboplatin meet dual primary endpoints in a confirmatory phase III study for the first-line treatment of lung cancer.

              Ophthotech Begins Phase II Zimura Study in Stargardt Disease

              by Zacks Equity Research

              Ophthotech (OPHT) is focusing on Zimura following the failure of the Fovista studies.

                Exelixis, Ipsen Report Positive Results on Lead Cancer Drug

                by Zacks Equity Research

                Exelixis (EXEL) and Ipsen announce detailed results from the late stage study of lead drug Cabometyx in patients with previously treated advanced HCC.

                  Will Amgen (AMGN) Continue to Tread Growth Path This Year?

                  by Zacks Equity Research

                  Amgen (AMGN) stock outperformed the industry in 2017. We will have to wait and see if it can keep the momentum alive in 2018.

                    Why is Puma (PBYI) Stock Up More than 150% in a Year's Time?

                    by Zacks Equity Research

                    Puma's (PBYI) shares jump in a year's time on its cancer drug Nerlynx's approval in the United States coupled with strategic collaborations.

                      Prothena (PRTA) Tumbles 18% in a Year: What Lies Ahead?

                      by Zacks Equity Research

                      Prothena's (PRTA) stock tumbles more than 18% due to a pipeline setback. The company depends heavily on the success of its two candidates.

                        Roche MS Drug Ocrevus Gets Marketing Authorization in Europe

                        by Zacks Equity Research

                        Roche's (RHHBY) multiple sclerosis drug Ocrevus gets approval in Europe thereby boosting its neuroscience portfolio. The drug is already approved in the United States.

                          Arpita Dutt headshot

                          FDA Approvals Surge in 2017: Here's a Look at the Numbers

                          by Arpita Dutt

                          There was a significant surge in FDA approvals in 2017 with the regulatory body giving its nod to 46 novel drugs plus gene-based therapies like Novartis's (NVS) Kymriah. Here is a closer look at the numbers and what lies ahead.

                            GE Healthcare Partners Roche for Improved Critical Care

                            by Zacks Equity Research

                            General Electric Company's (GE) segment GE Healthcare will now help to create a digital platform with Roche to advance medicinal treatments particularly for cancer and critical care patients.

                              Exelixis Amends Cabozantinib-Tecentriq Phase Ib Trial

                              by Zacks Equity Research

                              Exelixis, Inc. (EXEL) announced an amendment to the protocol for the phase Ib trial of cabozantinib combined with Tecentriq whereby there will be four new expansion cohorts to the trial.

                                ImmunoGen Starts Phase I Study on Leukemia Candidate IMGN632

                                by Zacks Equity Research

                                ImmunoGen (IMGN) begins a phase I study to evaluate its anti-CD123 antibody-drug conjugates, IMGN632, for treating patients with hematological malignancies.

                                  Cancer Space Update: New Regulatory Status for 3 Major Drugs

                                  by Zacks Equity Research

                                  Merck's Keytruda receives approval in Japan for bladder cancer. Seattle Genetics' Adcetris and Novartis' Kisqali get regulatory status updates from the FDA.

                                    Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod

                                    by Zacks Equity Research

                                    Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.

                                      Arpita Dutt headshot

                                      Pharma Stock Roundup: Allergan Announces Job Cuts, Pfizer Inks Deals

                                      by Arpita Dutt

                                      In a relatively slow week, Allergan's (AGN) job cut announcement remained the key highlight while Pfizer's collaboration agreements with Sangamo and Arvinas were also in focus.

                                        3 Large-Cap Pharma Stocks to Watch Out for This New Year

                                        by Zacks Equity Research

                                        We take a look at a few Large Cap drug stocks with a favorable combination of Zacks Rank and VGM Score. The stocks are poised to carry on their bull run this year too.

                                          Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018?

                                          by Zacks Equity Research

                                          AbbVie Inc. (ABBV) shares are expected to be northbound in 2018, carrying on the momentum achieved last year.

                                            Novartis Gets Second Breakthrough Designation for Kisqali

                                            by Zacks Equity Research

                                            Novartis (NVS) announces that the FDA has granted the second breakthrough designation to breast cancer drug, Kisqali, for the initial endocrine-based treatment of pre- or peri-menopausal women with HR+/HER2- advanced or metastatic breast cancer.

                                              Swarup Gupta headshot

                                              Foreign Stock Roundup: Roche to Buy Ignyta for $1.7B; Shell to Acquire First Utility

                                              by Swarup Gupta

                                              Global markets traversed a holiday shortened week marked by thin trading volumes.

                                                Arpita Dutt headshot

                                                3 Biotech and Pharma Stocks with FDA Catalysts this January

                                                by Arpita Dutt

                                                2017 saw the FDA approving 46 novel drugs as well as path-breaking treatments like Novartis's (NVS) Kymriah and Gilead's Yescarta. Here is a look at three companies expecting a decision this January.

                                                  The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S

                                                  by Zacks Equity Research

                                                  The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S